SharesGrow Score — EPIX | ESSA Pharma Inc.

← All Scored Tickers

ESSA Pharma Inc. EPIX

SharesGrow 7-Criteria Evaluation

56/100

SharesGrow Score

3/7 criteria passed

✓

VALUE 通过

Is the stock reasonably priced for its earnings and growth?

How we measure: Composite of trailing P/E vs S&P avg (20%), forward PEG (35%), price target upside — how far below analyst target (25%), and trailing PEG (20%). Trading far below target = high score. Composite ≥ 60 = Pass.

→ View Intrinsic Value

FUTURE 部分

Are analysts forecasting strong future growth?

How we measure: Primarily based on analyst consensus. ≥ 70% buy ratings = Pass (unless target implies > 15% downside). 50-70% = Partial. Price target upside is a bonus, not a requirement.

→ View Forecast

✗

PAST 未通过

Has the company been consistently profitable?

How we measure: Checks profitability in each of the last 4 fiscal years. Pass = profitable all 4 years.

0/4 yrs

Profitable yrs

$-0.64

EPS

→ View Income Statement

✓

HEALTH 通过

Is the balance sheet strong and debt manageable?

How we measure: Evaluates debt-to-equity (< 0.5 ideal), current ratio (> 1.5 ideal), and interest coverage (> 8x ideal).

→ View Health

✗

MOAT 未通过

Does the company have a durable competitive advantage?

How we measure: Composite score: gross margin level (35%) + gross margin trend (15%) + market cap size (30%) + revenue size (20%). Score ≥ 70 = Pass.

28/100

Moat score

Gross margin

+0pp

GM trend

$10M

Market cap

→ View Income Statement

✓

GROWTH 通过

Is the company growing revenue and earnings consistently?

How we measure: Average annual revenue growth and net income growth over the last 3–4 years. Both must exceed 5%/yr for Pass.

+0%/yr

Avg rev growth

+7.2%/yr

Avg NI growth

→ View Income Statement

✗

INCOME 未通过

Is the company generating strong profit margins?

How we measure: Net profit margin of the latest fiscal year. ≥ 15% = Pass, > 0% = Partial, negative = Fail.

Net margin

—

Revenue

→ View Income Statement

Score last updated: 2026-04-15 05:15:50

获取低估股票提醒